Fundraising Fox
Mondegobio
Cantanhede, PT · 4 employees on LinkedIn · 1 known investors
Find your way into Mondegobio
Sign up to find every way you can get introduced to Mondegobio
- Your email: who you already know at Mondegobio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Mondegobio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.
Investors · 1
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Mondegobio do?
- Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.
- Who are Mondegobio's investors?
- Mondegobio's investors include OrbiMed.
- Where is Mondegobio headquartered?
- Mondegobio is headquartered in Cantanhede, PT.